Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients.

1. Treat Infection of Multiple HPV Virus Strains via Trained Immunity.
2. Activate human HPV Antigen Presentation Reaction.
3. The human antigen presenting cells (APCs) can treat the HPV virus protein antigens into small peptide fragments, and then clear HPV virus in vivo.

• Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix activity that suggests the potential for clinical benefit of HPV patients
• 20 Cervical HPV Infection Patients
• Positive testing HPV by standard PCR assay
• HPV infection without symptoms
• No clinical signs indicative of oncology
• TB negative participant is negative IGRA blood test with TB antigens
• 9vHPV Vaccine 1.0 mL plus BCG Organism 50 MG Mix
• By the percutaneous route with the multiple puncture device
• Negative testing HPV by standard PCR assay after percutaneous 21 days
• Positive IGRA blood test with HPV protein antigen after percutaneous use 21 days
• Our trial duration will be 12-week duration.

Conducting an early phase clinical trial to assess HPV Antigen Presentation Therapeutic Biological Product Mix that suggests the potential for clinical benefit of HPV patients.

20 Cervical HPV Infection Patients

Inclusion Criteria:

• Cervical HPV Infection Patients
• Positive testing HPV by standard PCR assay
• HPV infection without symptoms
• No clinical signs indicative of oncology
• TB negative participant is negative IGRA blood test with TB antigens

Exclusion Criteria:

• Pregnant
• Thrombosis
• Bleeding
• Allergy
• TB positive participant is positive IGRA blood test with TB antigens
• Symptoms of HPV infection
• Clinical signs suggestive of other infection
• Symptoms suggestive of other infection
• Clinical signs indicative of oncology
• Evidence of critical illness

Cervical is a female organ.

Open Label